Gastroenterology

  • Home
  • Gastroenterology
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)

Condition:   Diabetic Macular Edema
Interventions:   Drug: Aflibercept;   Drug: Faricimab;   Drug: Sham Procedure
Sponsor:   Hoffmann-La Roche
Recruiting
ClinicalTrials.gov: Gastroenterology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

October 22, 2018 / by / in
A Study to Investigate How Well ABBV-323 Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy

Condition:   Ulcerative Colitis (UC)
Interventions:   Drug: ABBV-323 Dose A;   Drug: ABBV-323 Dose B;   Drug: Placebo
Sponsor:   AbbVie
Not yet recruiting
ClinicalTrials.gov: Gastroenterology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

October 4, 2018 / by / in
AI-EMERGE: Development and Validation of a Multi-analyte, Blood-based Colorectal Cancer Screening Test

Conditions:   Colo-rectal Cancer;   Cancer Colon;   Cancer, Rectum;   Neoplasms,Colorectal;   Polyps;   Polyp of Colon;   Adenoma;   Adenoma Colon
Intervention:  
Sponsor:   Freenome, Inc.
Recruiting
ClinicalTrials.gov: Gastroenterology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

September 28, 2018 / by / in
Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza

Condition:   Influenza
Interventions:   Drug: Baloxavir Marboxil;   Other: Placebo
Sponsor:   Hoffmann-La Roche
Not yet recruiting
ClinicalTrials.gov: Gastroenterology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

September 26, 2018 / by / in
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Condition:   Primary Biliary Cholangitis
Interventions:   Drug: seladelpar 5-10 mg;   Drug: seladelpar 10 mg;   Drug: Placebo
Sponsor:   CymaBay Therapeutics, Inc.
Recruiting
ClinicalTrials.gov: Gastroenterology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

September 15, 2018 / by / in
A Study of the Safety, Efficacy and Tolerability of Nexvax-2 in Patients With Celiac Disease (CeD)

Conditions:   Celiac Disease;   Celiac;   Intestinal Disease;   Malabsorption Syndromes;   Gastrointestinal Disease;   Digestive System Disease;   Gluten Sensitivity;   Autoimmune Diseases
Interventions:   Biological: Nexvax2;   Biological: Placebo
Sponsor:   ImmusanT, Inc.
Recruiting
ClinicalTrials.gov: Gastroenterology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

September 9, 2018 / by / in
A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

Condition:   Colitis, Ulcerative
Interventions:   Drug: Guselkumab Dose 1;   Drug: Guselkumab Dose 2;   Drug: Golimumab Dose 1;   Drug: Golimumab Dose 2;   Drug: Placebo
Sponsor:   Janssen Research & Development, LLC
Not yet recruiting
ClinicalTrials.gov: Gastroenterology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

September 8, 2018 / by / in
Mepo for EoE Study

Conditions:   EoE;   Eosinophilic Esophagitis
Interventions:   Drug: Mepolizumab 300 mg;   Drug: Mepolizumab 100 mg;   Other: Placebo
Sponsors:   University of North Carolina, Chapel Hill;   GlaxoSmithKline;   University of Utah;   Northwestern University;   Minnesota Gastroenterology, P.A.
Not yet recruiting
ClinicalTrials.gov: Gastroenterology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

September 5, 2018 / by / in